tetano
Editor, Senior Moderator
J Infect Dis. 2018 May 31. doi: 10.1093/infdis/jiy328. [Epub ahead of print]
[h=1]Anti-influenza Hyperimmune Immunoglobulin Enhances Fc-functional Antibody Immunity during Human Influenza Infection.[/h] Vanderven HA[SUP]1[/SUP], Wragg K[SUP]1[/SUP], Ana-Sosa-Batiz F[SUP]1[/SUP], Kristensen AB[SUP]1[/SUP], Jegaskanda S[SUP]1[/SUP], Wheatley AK[SUP]1[/SUP], Wentworth D[SUP]2[/SUP], Wines BD[SUP]3[/SUP], Hogarth PM[SUP]3[/SUP], Rockman S[SUP]1,[/SUP][SUP]4[/SUP]; INSIGHT FLU005 Pilot Study Writing Group, Kent SJ[SUP]1,[/SUP][SUP]5,[/SUP][SUP]6[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]Background:[/h] New treatments for severe influenza are needed. Passive transfer of influenza-specific hyperimmune pooled immunoglobulin (Flu-IVIG) boosts neutralising antibody responses to past strains in influenza-infected subjects. The effect of Flu-IVIG on antibodies with Fc-mediated functions, which may target diverse influenza strains, is unclear.
[h=4]Methods:[/h] We studied the capacity of Flu-IVIG, relative to standard IVIG, to bind to Fc receptors and mediate antibody-dependent cellular cytotoxicity in vitro. The effect of Flu-IVIG infusion, compared to placebo infusion, was examined in serial plasma samples from 24 subjects with confirmed influenza infection in the INSIGHT FLU005 pilot study.
[h=4]Results:[/h] Flu-IVIG contains higher concentrations of Fc-functional antibodies than IVIG against a diverse range of influenza hemagglutinins. Following infusion of Flu-IVIG into influenza-infected subjects, a transient increase in Fc-functional antibodies was present for 1-3 days against infecting and non-infecting strains of influenza.
[h=4]Conclusions:[/h] Flu-IVIG contains antibodies with Fc-mediated functions against influenza virus and passive transfer of Flu-IVIG increases anti-influenza Fc-functional antibodies in the plasma of influenza-infected subjects. Enhancement of Fc-functional antibodies to a diverse range of influenza strains suggests that Flu-IVIG infusion could prove useful in the context of novel influenza virus infections, when there may be minimal or no neutralising antibodies in the Flu-IVIG preparation.
PMID: 29860297 DOI: 10.1093/infdis/jiy328
[h=1]Anti-influenza Hyperimmune Immunoglobulin Enhances Fc-functional Antibody Immunity during Human Influenza Infection.[/h] Vanderven HA[SUP]1[/SUP], Wragg K[SUP]1[/SUP], Ana-Sosa-Batiz F[SUP]1[/SUP], Kristensen AB[SUP]1[/SUP], Jegaskanda S[SUP]1[/SUP], Wheatley AK[SUP]1[/SUP], Wentworth D[SUP]2[/SUP], Wines BD[SUP]3[/SUP], Hogarth PM[SUP]3[/SUP], Rockman S[SUP]1,[/SUP][SUP]4[/SUP]; INSIGHT FLU005 Pilot Study Writing Group, Kent SJ[SUP]1,[/SUP][SUP]5,[/SUP][SUP]6[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]Background:[/h] New treatments for severe influenza are needed. Passive transfer of influenza-specific hyperimmune pooled immunoglobulin (Flu-IVIG) boosts neutralising antibody responses to past strains in influenza-infected subjects. The effect of Flu-IVIG on antibodies with Fc-mediated functions, which may target diverse influenza strains, is unclear.
[h=4]Methods:[/h] We studied the capacity of Flu-IVIG, relative to standard IVIG, to bind to Fc receptors and mediate antibody-dependent cellular cytotoxicity in vitro. The effect of Flu-IVIG infusion, compared to placebo infusion, was examined in serial plasma samples from 24 subjects with confirmed influenza infection in the INSIGHT FLU005 pilot study.
[h=4]Results:[/h] Flu-IVIG contains higher concentrations of Fc-functional antibodies than IVIG against a diverse range of influenza hemagglutinins. Following infusion of Flu-IVIG into influenza-infected subjects, a transient increase in Fc-functional antibodies was present for 1-3 days against infecting and non-infecting strains of influenza.
[h=4]Conclusions:[/h] Flu-IVIG contains antibodies with Fc-mediated functions against influenza virus and passive transfer of Flu-IVIG increases anti-influenza Fc-functional antibodies in the plasma of influenza-infected subjects. Enhancement of Fc-functional antibodies to a diverse range of influenza strains suggests that Flu-IVIG infusion could prove useful in the context of novel influenza virus infections, when there may be minimal or no neutralising antibodies in the Flu-IVIG preparation.
PMID: 29860297 DOI: 10.1093/infdis/jiy328